CVI Holdings’s Benitec Biopharma BNTC Stock Holding History

CVI Holdings’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-75,831	Closed	-$479K	–	622
2022 Q3	$479K	Buy	+75,831	New	+$963K	0.04%	404

Other funds holding BNTC

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

CVI Holdings's BNTC Position: Q4 2022 in Review

CVI Holdings sold out of Benitec Biopharma (BNTC) in Q4 2022, closing a stake of 75,831 shares — an estimated $479K sold.

CVI Holdings first reported a position in BNTC in Q3 2022 and held it in 1 quarter. The position peaked at $479K in Q3 2022. 25 funds tracked by Wall St. Rank hold BNTC as of Q4 2022.

CVI Holdings reported no remaining Benitec Biopharma position as of Q4 2022 after selling out during the quarter.
CVI Holdings sold 75,831 Benitec Biopharma shares in Q4 2022, an estimated $479K.
CVI Holdings first reported a position in Benitec Biopharma in Q3 2022 and held it in 1 quarter.
CVI Holdings's Benitec Biopharma position peaked at $479K in Q3 2022.
25 funds tracked by Wall St. Rank held Benitec Biopharma as of Q4 2022.

Based on CVI Holdings's 13F filing for Q4 2022, filed 14 Feb 2023.